Piper Sandler raised the firm’s price target on Aquestive Therapeutics (AQST) to $8 from $5 and keeps an Overweight rating on the shares after hosting a fireside chat with the company’s senior leadership ahead of data presentations for Anaphylm at the upcoming American College of Allergy, Asthma and Immunology meeting. Key discussion topics included the body of data surrounding the product; the NDA review process; and commercial launch plans. Piper remains confident in a timely FDA approval of Anaphylm, and believes the product will be met with an enthusiastic prescriber audience.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Reports Q3 2025 Financial Results
- Aquestive Therapeutics’ Earnings Call: Optimism Amid Challenges
- Aquestive Therapeutics Advances Anaphylm Towards FDA Approval
- Positive Outlook for Aquestive Therapeutics: Buy Rating Driven by Strong Pipeline, Financial Position, and Upcoming PDUFA Date
- Aquestive Therapeutics reports Q3 EPS (14c), consensus (11c)